According to a new study, choosing colon cancer may be beneficial to male patients, while not as a female benefit.
The study appeared in the British Journal of Surgery. Colon cancer is the most common form of the third world cancer. Every year, about 3,000 new cases are diagnosed and approximately 1,200 patients have died.
Between 2004 and 2016, the dissemination of Finnish projects was extended to explore the benefits and disadvantages of a nationwide study on colon cancer.
Targeted at the 60-69 age group, with less than half the age group or more than 300,000 people, they were distributed at the end of 2011. Half of the population of the study was invited to the project, the other half were the cohort control group. Prophylactory blood-tested test (FOBT) factors were used, and they referred to a colonoscopy of patients who tested positive blood.
The first study based on the results of the study did not make a significant drop in the death rate, the projections that were taken since 2016. However, researchers from the Helsinki University Hospital and the Finnish Cancer Registry demonstrated that this study provided patients with cancer of the colon cancer. .
"In cases of non-invasive cancer-related effects on cancer can be useful in other ways. We have tried to analyze whether or not patients can avoid liver treatments, to be colon cancer." said Dr. Laura Koskenvuo.
In the study, he analyzed the 1,400 patients diagnosed with colon cancer. According to the results, screening in the group among patients, the elimination of the total tumor was more successful than the surgical control patients and at least required chemotherapy. Because the projection team was not subjected to an emergency surgery due to tumors that only controlled patients due to emergency surgery.
"Control groups accounted for 50% more emergency trials, 40% more, unstable tumors and 20% more chemotherapy treatments than in the group of performances," said Ville Sallin, a gastrointestinal surgeon.
A closer examination of the results shows that these benefits are particularly prevalent among males. There were no similar benefits amongst women.
Furthermore, the researchers demonstrated that efficacy was effective in detecting left-wing colon cancer and proving that it was beneficial for cancer-based cancer, because it is likely to dilute the blood from the tumors on the right side. It hits that gFOBT is no longer detected.
"In the future, we have to investigate whether different operation techniques can improve the condition of the patients and diagnose cancer of the right colon," said the researchers.
(This story is not edited by Business Standard staff and is created by a syndicated feed.)